Vincent Goldschmidt

5PUBLICATIONS
46CO-AUTHORS
Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Liquid biopsiesHaematological tumours
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (5)

|Sep 23, 2026
Gustave Roussy Immune Score Validation in Patients Treated with Bispecific CD3 T-cell Engagers in Phase I Clinical Trials.

|Nov 06, 2025
First-in-Human, Phase I/II Dose Escalation and Expansion Study of Zelenectide Pevedotin in Patients With Advanced Solid Tumors: Results From Monotherapy Dose Escalation.

Capucine Baldini, Loic Verlingue, Vincent Goldschmidt

|May 30, 2024
Impact of Clonal Hematopoiesis-Associated Mutations in Phase I Patients Treated for Solid Tumors: An Analysis of the STING Trial.

Julieta Rodriguez, Capucine Baldini, Arnaud Bayle

|Jan 06, 2023
Sequence analyses of relapsed or refractory diffuse large B-cell lymphomas unravel three genetic subgroups of patients and the GNA13 mutant as poor prognostic biomarker, results of LNH-EP1 study.

Jean-Marie Michot, Cyril Quivoron, Clémentine Sarkozy

Pageof 1

Frequent Collaborators

3 joint publications

Jean-Marie Michot

3 joint publications

Capucine Baldini

2 joint publications

Kaissa Ouali

2 joint publications

Christophe Massard